论文部分内容阅读
目的 :观察巴曲酶对急性缺血性脑卒中患者外周血白细胞黏附分子和血清中可溶性黏附分子表达水平的影响。 方法 :治疗组 18例 ,予巴曲酶 3d(2 0 BU )并予其他常规治疗 ;对照组 18例 ,除未予巴曲酶外 ,余用药同巴曲酶治疗组。采用流式细胞术和酶联免疫吸附法测定患者卒中后不同时间外周血中性粒细胞和单核细胞 CD11b、CD18、CD6 2 L、CD5 4的表达以及血清中可溶性 ICAM- 1、VCAM- 1的水平。结果 :与对照组比 ,巴曲酶治疗组卒中患者在发病 2 4 h后中性粒细胞 CD11b的表达下降 (P<0 .0 5 ) ,单核细胞 CD11b、中性粒细胞和单核细胞 CD18、CD6 2 L、CD5 4的表达及血清中可溶性 ICAM- 1、VCAM- 1的水平均无显著性变化。 结论 :巴曲酶对急性缺血性脑卒中患者外周血黏附分子的表达的影响有限 ,提示降低外周血黏附分子的表达可能不是巴曲酶治疗缺血性脑卒中的主要作用机制
Objective: To observe the effect of batroxobin on peripheral leukocyte adhesion molecules and serum soluble adhesion molecule expression in patients with acute ischemic stroke. Methods: 18 cases in the treatment group were treated with batroxobin 3 days (20 BU) and were given routine treatment. In the control group, 18 cases were treated with Batroxobin except batroxobin. Flow cytometry and enzyme-linked immunosorbent assay were used to detect the expression of CD11b, CD18, CD62L and CD54 in peripheral blood mononuclear cells and soluble ICAM-1, VCAM-1 s level. Results: Compared with the control group, the expression of CD11b in the neutrophils was decreased in the patients with stroke after batroxobin treatment (P <0.05), the levels of CD11b, neutrophils and monocytes CD18, CD6 2 L, CD5 4 expression and serum soluble ICAM-1, VCAM-1 levels did not change significantly. Conclusion: Batroxobin has a limited effect on the expression of peripheral blood adhesion molecules in patients with acute ischemic stroke, suggesting that decreasing the expression of peripheral blood adhesion molecules may not be the main mechanism of action of batroxobin in the treatment of ischemic stroke